Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: date men + 0.20 + web  Related to the article below (Last Update: 8/4/2008)

Athletics: With Beijing A Glance Away, Golden League Resumes In Rome
RunnersWeb, Canada - Jul 10, 2008
In the Eugene race, it was all Merritt, who won by a whopping 0.20 seconds in 44.00. But the pair said today that their latest showdown is behind them. ...
Source: Google News

[PDF] BMC Genetics
D Levy, SR DePalma, EJ Benjamin, CJ O'Donnell, H … - BMC Genetics, 2006 - biomedcentral.com
... Acceptance date 22 May 2006 Publication date 22 May 2006 ... Linux/AOLserver/Oracle/
ACS web server platform. ... Men 0.20 0.70 0.01 0.16 0.04 0.26 ...

[CITATION] Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV … -
R Detels, A Munoz, G McFarlane, LA Kingsley, JB … - JAMA: The Journal of the American Medical Association, 1998 - JAMA
... methods with time zero set as the date of seroconversion ... of 231 seroconverters developed
AIDS, and 200 men died ... to July 1995 and 0.35 (95% CI, 0.20-0.61) during ...

Real life information retrieval: a study of user queries on the Web -
BJ Jansen, A Spink, J Bateman, T Saracevic - ACM SIGIR Forum, 1998 - portal.acm.org
... However, to date there has been no large-scale, quantitative or qualitative ... 9 36
0.20 ... naked adult shate big for 340 basketball new i334 men 330 employment 291 ...

Theme: Alcohol attributable crime Indicator: Crude rate, all ages,?, persons
G Persons, E Date, URL Source - healthintelligence.bmj.com
... Age was calculated from date of birth and the start date of the ... Binge drinking was
defined separately for men and women: men were defined as ... C16 0.20 0.20 ...

Theme: Alcohol related hospital admission Indicator: DS rate, all ages, FY 2004/5, males
G Males, E Date, URL Source - healthintelligence.bmj.com
... Age was calculated from date of birth and the start date of the ... Binge drinking was
defined separately for men and women: men were defined as ... C16 0.20 0.20 ...

Theme: Alcohol related hospital admission Indicator: DS rate, all ages, FY 2004/5, females
G Females, E Date, URL Source - healthintelligence.bmj.com
... Age was calculated from date of birth and the start date of the ... Binge drinking was
defined separately for men and women: men were defined as ... C16 0.20 0.20 ...

Theme: Alcohol specific hospital admission Indicator: DS rate, all ages, FY 2004/5, females
G Females, E Date, URL Source - healthintelligence.bmj.com
... Age was calculated from date of birth and the start date of the ... Binge drinking was
defined separately for men and women: men were defined as ... C16 0.20 0.20 ...

Theme: Alcohol specific hospital admission Indicator: DS rate, all ages, FY 2004/5, males
G Males, E Date, URL Source - healthintelligence.bmj.com
... Age was calculated from date of birth and the start date of the ... Binge drinking was
defined separately for men and women: men were defined as ... C16 0.20 0.20 ...

Plasma Adiponectin Levels and Risk of Myocardial Infarction in Men -
T Pischon, CJ Girman, GS Hotamisligil, N Rifai, FB … - JAMA, 2004 - Am Med Assoc
... Men who provided samples were somewhat younger but were otherwise similar ... 2:1 ratio
and matched for age, date of blood ... levels of at least 150 mg/dL (0.20 mmol/L ...

[CITATION] Vasectomy and Risk of Prostate Cancer -
B Cox, MJ Sneyd, C Paul, B Delahunt, DCG Skegg - JAMA: The Journal of the American Medical Association, 2002 - JAMA
... RR was reduced further (RR, 0.53; 95% CI, 0.20-1.41) but ... to have a DRE before their
date of diagnosis. Men whose cancer was diagnosed through investigation for ...

Source: Google Scholar
 
 

Combination Therapy Appears More Effective Than Single Drug For Lower Urinary Tract Symptoms

Article Date: 18 Nov 2006 - 17:00pm (PST)
Men with overactive bladder and lower urinary tract symptoms who received a combination therapy were more likely to report improvement in symptoms than men who received only one medication, according to a study in the November 15 issue of JAMA, a theme issue on men's health.

Steven A. Kaplan, M.D., of Weill Cornell Medical College, New York, presented the findings of the study on 14-Nov-2006 at a JAMA media briefing on men's health in New York.

Overactive bladder is a syndrome characterized by urinary urgency, usually with increased urination frequency during the day and night. An estimated 10 million men 40 years or older have symptoms consistent with overactive bladder, according to background information in the article. Lower urinary tract symptoms include urinary hesitancy and intermittency and weak urinary stream. Some men with these symptoms do not respond to treatment with common medications.

Article continues below and (thank you)
 
Dr. Kaplan and colleagues evaluated the effectiveness of two widely used medications, tolterodine extended release (ER), an antimuscarinic, and tamsulosin, an ᱭreceptor antagonist, used alone or in combination in men with overactive bladder and benign prostatic hyperplasia (enlarged prostate). The randomized, double-blind trial was conducted at 95 urology clinics in the United States involving men 40 years or older who had a self-rated bladder condition of at least moderate bother, and a bladder diary documenting urination frequency (8 or more urinations per 24 hours) and urgency (3 or more episodes per 24 hours), with or without urgency urinary incontinence. Patients were randomly assigned to receive placebo (n = 222), 4 mg of tolterodine ER (n = 217), 0.4 mg of tamsulosin (n = 215), or both tolterodine ER plus tamsulosin (n = 225) for 12 weeks. Patients were recruited between November 2004 and February 2006, and the study was completed May 2006.

The researchers found that 80 percent of patients receiving tolterodine ER plus tamsulosin reported treatment benefit by week 12, compared with 62 percent of patients receiving placebo, 65 percent of patients receiving tolterodine ER, or 71 percent of patients receiving tamsulosin. Neither group receiving monotherapy demonstrated significant differences vs. placebo in percentages of patients reporting treatment benefit.
 
The symptoms of urgency urinary incontinence, urgency, and 24-hour and nocturnal urination frequency were also significantly improved by week 12 in the group receiving tolterodine ER plus tamsulosin vs. placebo but not in the tamsulosin group. In the tolterodine ER group, only urgency urinary incontinence episodes per 24 hours were significantly reduced at week 12. The International Prostate Symptom Score and quality-of-life scores were significantly improved by week 12 among patients receiving tolterodine ER plus tamsulosin. All interventions were well tolerated.

"The results of this study demonstrate that some men bothered by lower urinary tract symptoms, including bladder diary-documented overactive bladder symptoms, might not respond to monotherapy with either ᭲eceptor antagonists or antimuscarinic agents. Treatment with tolterodine ER plus tamsulosin resulted in statistically and clinically significant treatment benefit. Similarly low incidences of acute urinary retention were observed in all treatment groups, and there were no significant differences in maximum urinary flow rate or postvoid residual volume between any 2 groups," the authors conclude.

###

(JAMA. 2006;296:2319-2328.)

This study was funded by Pfizer Inc. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Contact: Jonathan Weil
JAMA and Archives Journals
 
Google
Web www.iconocast.com